RBCK1 is an Endogenous Inhibitor for Triple Negative Breast Cancer Via Hippo/YAP Axis

Overview

Journal Cell Commun Signal

Publisher Biomed Central

Specialties Biochemistry
Cell Biology

Date 2022 Oct 25

PMID 36280829

Authors

Zhongbo Li

Peng Su

Yinlu Ding

Honglei Gao

Huijie Yang

Xin Li

Xiao Yang

Yan Xia

Chenmiao Zhang

Mingxi Fu

Dehai Wang

Ye Zhang

Shu Zhuo

Jian Zhu

Ting Zhuang

Affiliations

Soon will be listed here.

Abstract

Background: Triple negative breast cancer (TNBC) is one of the most lethal breast cancer subtypes. Due to a lack of effective therapeutic targets, chemotherapy is still the main medical treatment for TNBC patients. Thus, it is important and necessary to find new therapeutic targets for TNBC. Recent genomic studies implicated the Hippo / Yap signal is over activated in TNBC, manifesting it plays a key role in TNBC carcinogenesis and cancer progression. RBCK1 was firstly identified as an important component for linear ubiquitin assembly complex (LUBAC) and facilitates NFKB signaling in immune response. Further studies showed RBCK1 also facilitated luminal type breast cancer growth and endocrine resistance via trans-activation estrogen receptor alpha.

Methods: RBCK1 and YAP protein expression levels were measured by western blotting, while the mRNA levels of YAP target genes were measured by RT-PCR. RNA sequencing data were analyzed by Ingenuity Pathway Analysis. Identification of Hippo signaling activity was accomplished with luciferase assays, RT-PCR and western blotting. Protein stability assays and ubiquitin assays were used to detect YAP protein degradation. Ubiquitin-based immunoprecipitation assays were used to detect the specific ubiquitination modification on the YAP protein.

Results: In our current study, our data revealed an opposite function for RBCK1 in TNBC progression. RBCK1 over-expression inhibited TNBC cell progression in vitro and in vivo, while RBCK1 depletion promoted TNBC cell invasion. The whole genomic expression profiling showed that RBCK1 depletion activated Hippo/YAP axis. RBCK1 depletion increased YAP protein level and Hippo target gene expression in TNBC. The molecular biology studies confirmed that RBCK1 could bind to YAP protein and enhance the stability of YAP protein by promoting YAP K48-linked poly-ubiquitination at several YAP lysine sites (K76, K204 and K321).

Conclusion: Our study revealed the multi-faced RBCK1 function in different subtypes of breast cancer patients and a promising therapeutic target for TNBC treatment. Video abstract.

Citing Articles

USP12 facilitates gastric cancer progression via stabilizing YAP.

Zhang P, Liu D, Zang Y, Wang J, Liu Z, Zhu J Cell Death Discov. 2024; 10(1):174.

PMID: 38605077 PMC: 11009230. DOI: 10.1038/s41420-024-01943-2.

RBCK1 overexpression is associated with immune cell infiltration and poor prognosis in hepatocellular carcinoma.

Yu J, Liu T, Liu M, Jin H, Wei Z Aging (Albany NY). 2024; 16(1):538-549.

PMID: 38214606 PMC: 10817371. DOI: 10.18632/aging.205393.

Mechanisms underlying linear ubiquitination and implications in tumorigenesis and drug discovery.

Li J, Liu S, Li S Cell Commun Signal. 2023; 21(1):340.

PMID: 38017534 PMC: 10685518. DOI: 10.1186/s12964-023-01239-5.

Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer.

Wang T, Wang D, Sun Y, Zhuang T, Li X, Yang H J Exp Clin Cancer Res. 2023; 42(1):297.

PMID: 37950281 PMC: 10636825. DOI: 10.1186/s13046-023-02870-3.

Wang W, Zhou Q, Lan L, Xu X Sci Rep. 2023; 13(1):8449.

PMID: 37231081 PMC: 10213036. DOI: 10.1038/s41598-023-35462-4.

References

Darbeheshti F, Mahdiannasser M, Noroozi Z, Firoozi Z, Mansoori B, Daraei A . Circular RNA-associated ceRNA network involved in HIF-1 signalling in triple-negative breast cancer: circ_0047303 as a potential key regulator. J Cell Mol Med. 2021; 25(24):11322-11332. PMC: 8650046. DOI: 10.1111/jcmm.17066. View

Liu Y, Su P, Zhao W, Li X, Yang X, Fan J . ZNF213 negatively controls triple negative breast cancer progression via Hippo/YAP signaling. Cancer Sci. 2021; 112(7):2714-2727. PMC: 8253295. DOI: 10.1111/cas.14916. View

Wang D, Li Z, Li X, Yan C, Yang H, Zhuang T . DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer. J Exp Clin Cancer Res. 2022; 41(1):219. PMC: 9275142. DOI: 10.1186/s13046-022-02410-5. View

Frangou C, Li Y, Shen H, Yang N, Wilson K, Blijlevens M . Molecular profiling and computational network analysis of TAZ-mediated mammary tumorigenesis identifies actionable therapeutic targets. Oncotarget. 2014; 5(23):12166-76. PMC: 4323005. DOI: 10.18632/oncotarget.2570. View

Chen W, Bai Y, Patel C, Geng F . Autophagy promotes triple negative breast cancer metastasis via YAP nuclear localization. Biochem Biophys Res Commun. 2019; 520(2):263-268. DOI: 10.1016/j.bbrc.2019.09.133. View

Beasley S, Safadi S, Barber K, Shaw G . Solution structure of the E3 ligase HOIL-1 Ubl domain. Protein Sci. 2012; 21(7):1085-92. PMC: 3403446. DOI: 10.1002/pro.2080. View

Kang W, Cheng A, Yu J, To K . Emerging role of Hippo pathway in gastric and other gastrointestinal cancers. World J Gastroenterol. 2016; 22(3):1279-88. PMC: 4716037. DOI: 10.3748/wjg.v22.i3.1279. View

Nagini S . Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anticancer Agents Med Chem. 2016; 17(2):152-163. DOI: 10.2174/1871520616666160502122724. View

Ding N, Huang T, Yuan J, Mao J, Duan Y, Liao W . Yes-associated protein expression in paired primary and local recurrent breast cancer and its clinical significance. Curr Probl Cancer. 2019; 43(5):429-437. DOI: 10.1016/j.currproblcancer.2018.12.005. View

10.

Zhou X, Li Y, Wang W, Wang S, Hou J, Zhang A . Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2. Theranostics. 2020; 10(21):9443-9457. PMC: 7449928. DOI: 10.7150/thno.46078. View

11.

Zhou R, Ding Y, Xue M, Xiong B, Zhuang T . RNF181 modulates Hippo signaling and triple negative breast cancer progression. Cancer Cell Int. 2020; 20:291. PMC: 7339498. DOI: 10.1186/s12935-020-01397-3. View

12.

Ma B, Cheng H, Gao R, Mu C, Chen L, Wu S . Zyxin-Siah2-Lats2 axis mediates cooperation between Hippo and TGF-β signalling pathways. Nat Commun. 2016; 7:11123. PMC: 4821889. DOI: 10.1038/ncomms11123. View

13.

Liedtke C, Bernemann C, Kiesel L, Rody A . Genomic profiling in triple-negative breast cancer. Breast Care (Basel). 2014; 8(6):408-13. PMC: 3919434. DOI: 10.1159/000357534. View

14.

Chan W, Marinho J, Chavarri-Guerra Y, Hincapie-Echeverri J, Velasco Jr R, Akagunduz B . Systemic treatment for triple negative breast cancer in older patients: A Young International Society of Geriatric Oncology Review Paper. J Geriatr Oncol. 2022; 13(5):563-571. DOI: 10.1016/j.jgo.2022.01.002. View

15.

Vici P, Ercolani C, Di Benedetto A, Pizzuti L, Di Lauro L, Sperati F . Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. J Exp Clin Cancer Res. 2016; 35:62. PMC: 4818869. DOI: 10.1186/s13046-016-0338-7. View

16.

Gustafsson N, Zhao C, Gustafsson J, Dahlman-Wright K . RBCK1 drives breast cancer cell proliferation by promoting transcription of estrogen receptor alpha and cyclin B1. Cancer Res. 2010; 70(3):1265-74. DOI: 10.1158/0008-5472.CAN-09-2674. View

17.

Li Y, Xu J, Zhu G, Huang Z, Lu Y, Li X . Apigenin suppresses the stem cell-like properties of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. Cell Death Discov. 2018; 4:105. PMC: 6244166. DOI: 10.1038/s41420-018-0124-8. View

18.

Moroishi T, Hansen C, Guan K . The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015; 15(2):73-79. PMC: 4562315. DOI: 10.1038/nrc3876. View

19.

Overholtzer M, Zhang J, Smolen G, Muir B, Li W, Sgroi D . Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A. 2006; 103(33):12405-10. PMC: 1533802. DOI: 10.1073/pnas.0605579103. View

20.

Tokunaga F, Iwai K . Linear ubiquitination: a novel NF-κB regulatory mechanism for inflammatory and immune responses by the LUBAC ubiquitin ligase complex. Endocr J. 2012; 59(8):641-52. DOI: 10.1507/endocrj.ej12-0148. View